B cells are required for sunlight protection of mice from a CNS-targeted autoimmune attack

Journal of Autoimmunity

Volumn 73, Issue , 2016, Pages 10-23

  Kok, Lai Fong ^a   Marsh Wakefield, Felix ^a   Marshall, Jacqueline E ^a   Gillis, Caitlin ^a   Halliday, Gary M ^a   Byrne, Scott N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Experimental autoimmune encephalomyelitis; Immune suppression; Multiple sclerosis; Regulatory B cells; Sunlight; Ultraviolet radiation

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; B7 ANTIGEN; CD19 ANTIGEN; CD86 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D RECEPTOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; PROGRAMMED DEATH 1 LIGAND 1; HLA ANTIGEN CLASS 2; IL10 PROTEIN, MOUSE; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; DEMYELINATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; SUNLIGHT PROTECTION; ULTRAVIOLET RADIATION; ANIMAL; C57BL MOUSE; CENTRAL NERVOUS SYSTEM; CHEMICALLY INDUCED; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; RADIATION RESPONSE; REGULATORY B LYMPHOCYTE; SUNLIGHT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; AUTOIMMUNITY; B-LYMPHOCYTES, REGULATORY; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-10; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; SUNLIGHT;

EID: 84991277861     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.05.016     Document Type: Article

References (82)

1. [1] Mohr, S.B., Garland, C.F., Gorham, E.D., Garland, F.C., The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia 51 (2008), 1391–1398.
2. [2] Armitage, E.L., Aldhous, M.C., Anderson, N., Drummond, H.E., Riemersma, R.A., Ghosh, S., et al. Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology 127 (2004), 1051–1057.
3. [3] Sonnenberg, A., McCarty, D.J., Jacobsen, S.J., Geographic variation of inflammatory bowel disease within the United States. Gastroenterology 100 (1991), 143–149.
4. [4] Ponsonby, A.L., Lucas, R.M., van der Mei, I.A., UVR, vitamin D and three autoimmune diseases–multiple sclerosis, type 1 diabetes, rheumatoid arthritis. Photochem. Photobiol. 81 (2005), 1267–1275.
5. [5] van der Mei, I.A.F., Ponsonby, A.L., Dwyer, T., Blizzard, L., Simmons, R., Taylor, B.V., et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ, 327, 2003, 316.
6. [6] Simpson, S., Blizzard, L., Otahal, P., Van der Mei, I., Taylor, B., Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 82 (2011), 1132–1141.
7. [7] Lucas, R.M., Byrne, S.N., Correale, J., Ilschner, S., Hart, P.H., Ultraviolet radiation, vitamin D and multiple sclerosis. Neurodegener. Dis. Manag. 5 (2015), 413–424.
8. [8] Davis, G.E., Lowell, W.E., Indirect evidence that ultraviolet-B radiation mitigates multiple sclerosis in the United States. J. Photochem. Photobiol. B 151 (2015), 46–47.
9. [9] Munger, K.L., Levin, L.I., Hollis, B.W., Howard, N.S., Ascherio, A., Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296 (2006), 2832–2838.
10. [10] Lucas, R.M., Ponsonby, A.L., Dear, K., Valery, P.C., Pender, M.P., Taylor, B.V., et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 76 (2011), 540–548.
11. [11] Byrne, S.N., How much sunlight is enough?. Photochem. Photobiol. Sci. 13 (2014), 840–852.
12. [12] Hauser, S.L., Weiner, H.L., Che, M., Shapiro, M.E., Gilles, F., Letvin, N.L., Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. J. Immunol. 132 (1984), 1276–1281.
13. [13] Becklund, B.R., Severson, K.S., Vang, S.V., Deluca, H.F., UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 6418–6423.
14. [14] Breuer, J., Schwab, N., Schneider-Hohendorf, T., Marziniak, M., Mohan, H., Bhatia, U., et al. Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Ann. Neurol. 75 (2014), 739–758.
15. [15] Bruhs, A., Schwarz, T., Schwarz, A., Prevention and mitigation of experimental autoimmune encephalomyelitis by murine β-defensins via induction of regulatory T cells. J. Investig. Dermatol. 136 (2016), 173–181.
16. [16] Rana, S., Rogers, L.J., Halliday, G.M., Systemic low-dose UVB inhibits CD8 T cells and skin inflammation by alternative and novel mechanisms. Am. J. Pathol. 178 (2011), 2783–2791.
17. [17] Brown, E.L., Rivas, J.M., Ullrich, S.E., Young, C.R., Norris, S.J., Kripke, M.L., Modulation of immunity to Borrelia burgdorferi by ultraviolet irradiation: differential effect on Th1 and Th2 immune responses. Eur. J. Immunol. 25 (1995), 3017–3022.
18. [18] McGlade, J.P., Gorman, S., Zosky, G.R., Larcombe, A.N., Sly, P.D., Finlay-Jones, J.J., et al. Suppression of the asthmatic phenotype by ultraviolet B-induced, antigen-specific regulatory cells. Clin. Exp. Allergy 37 (2007), 1267–1276.
19. [19] Singh, T.P., Huettner, B., Koefeler, H., Mayer, G., Bambach, I., Wallbrecht, K., et al. Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice. Am. J. Pathol. 178 (2011), 699–708.
20. [20] Chacón-Salinas, R., Limón-Flores, A.Y., Chávez-Blanco, A.D., Gonzalez-Estrada, A., Ullrich, S.E., Mast cell-derived IL-10 suppresses germinal center formation by affecting T follicular helper cell function. J. Immunol. 186 (2011), 25–31.
21. [21] Marsh-Wakefield, F., Byrne, S.N., Photoimmunology and multiple sclerosis. Curr. Top. Behav. Neurosci. 26 (2015), 117–141.
22. [22] Ullrich, S.E., Kripke, M.L., Mechanisms in the suppression of tumor rejection produced in mice by repeated UV irradiation. J. Immunol. 133 (1984), 2786–2790.
23. [23] Moodycliffe, A.M., Nghiem, D., Clydesdale, G., Ullrich, S.E., Immune suppression and skin cancer development: regulation by NKT cells. Nat. Immunol. 1 (2000), 521–525.
24. [24] Hart, P.H., Grimbaldeston, M.A., Swift, G.J., Jaksic, A., Noonan, F.P., Finlayjones, J.J., Dermal mast cells determine susceptibility to ultraviolet B-Induced systemic suppression of contact hypersensitivity responses in mice. J. Exp. Med. 187 (1998), 2045–2053.
25. [25] Grimbaldeston, M.A., Nakae, S., Kalesnikoff, J., Tsai, M., Galli, S.J., Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat. Immunol. 8 (2007), 1095–1104.
26. [26] Byrne, S.N., Limon-Flores, A.Y., Ullrich, S.E., Mast cell migration from the skin to the draining lymph nodes upon UV-irradiation represents a key step in the induction of immune suppression. J. Immunol. 180 (2008), 4648–4655.
27. [27] Byrne, S.N., Halliday, G.M., B cells activated in lymph nodes in response to ultraviolet irradiation or by interleukin-10 inhibit dendritic cell induction of immunity. J. Investig. Dermatol. 124 (2005), 570–578.
28. [28] Byrne, S.N., Ahmed, J., Halliday, G.M., Ultraviolet B but not A radiation activates suppressor B cells in draining lymph nodes. Photochem. Photobiol. 81 (2005), 1366–1370.
29. [29] Matsumura, Y., Byrne, S.N., Nghiem, D., Miyahara, Y., Ullrich, S.E., A role for inflammatory mediators in the induction of immunoregulatory B cells. J. Immunol. 177 (2006), 4810–4817.
30. [30] Wolf, S.D., Dittel, B.N., Hardardottir, F., Janeway, C.A., Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184 (1996), 2271–2278.
31. [31] Fillatreau, S., Sweenie, C.H., McGeachy, M.J., Gray, D., Anderton, S.M., B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3 (2002), 944–950.
32. [32] Lampropoulou, V., Hoehlig, K., Roch, T., Neves, P., Gómez, E.C., Sweenie, C.H., et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 180 (2008), 4763–4773.
33. [33] Matsushita, T., Yanaba, K., Bouaziz, J.D., Fujimoto, M., Tedder, T.F., Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Investig. 118 (2008), 3420–3430.
34. [34] Kala, M., Rhodes, S.N., Piao, W.H., Shi, F.D., Campagnolo, D.I., Vollmer, T.L., B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp. Neurol. 221 (2010), 136–145.
35. [35] Rafei, M., Hsieh, J., Zehntner, S., Li, M., Forner, K., Birman, E., et al. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat. Med. 15 (2009), 1038–1045.
36. [36] Sun, J.B., Czerkinsky, C., Holmgren, J., B lymphocytes treated in vitro with antigen coupled to cholera toxin B subunit induce antigen-specific Foxp3+ regulatory T cells and protect against experimental autoimmune encephalomyelitis. J. Immunol. 188 (2012), 1686–1697.
37. [37] Duddy, M., Niino, M., Adatia, F., Hebert, S., Freedman, M., Atkins, H., et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178 (2007), 6092–6099.
38. [38] Knippenberg, S., Peelen, E., Smolders, J., Thewissen, M., Menheere, P., Cohen Tervaert, J.W., et al. Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission. J. Neuroimmunol. 239 (2011), 80–86.
39. [39] Byrne, S.N., Spinks, N., Halliday, G.M., Ultraviolet-A irradiation of C57BL/6 mice suppresses systemic contact hypersensitivity or enhances secondary immunity depending on dose. J. Investig. Dermatol. 119 (2002), 858–864.
40. [40] Yanaba, K., Bouaziz, J.D., Haas, K.M., Poe, J.C., Fujimoto, M., Tedder, T.F., A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28 (2008), 639–650.
41. [41] McCandless, E.E., Wang, Q., Woerner, B.M., Harper, J.M., Klein, R.S., CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J. Immunol. 177 (2006), 8053–8064.
42. [42] McCandless, E.E., Piccio, L., Woerner, B.M., Schmidt, R.E., Rubin, J.B., Cross, A.H., et al. Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am. J. Pathol. 172 (2008), 799–808.
43. [43] Sarchio, S.N.E., Scolyer, R.A., Beaugie, C., McDonald, D., Marsh-Wakefield, F., Halliday, G.M., et al. Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin Cancer. J. Investig. Dermatol. 134 (2014), 1091–1100.
44. [44] Damian, D.L., Patterson, C.R., Stapelberg, M., Park, J., Barnetson, R.S., Halliday, G.M., UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J. Investig. Dermatol. 128 (2008), 447–454.
45. [45] Matsushita, T., Fujimoto, M., Hasegawa, M., Komura, K., Takehara, K., Tedder, T.F., et al. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am. J. Pathol. 168 (2006), 812–821.
46. [46] Olkhanud, P.B., Damdinsuren, B., Bodogai, M., Gress, R.E., Sen, R., Wejksza, K., et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res. 71 (2011), 3505–3515.
47. [47] Lang, P., Stolpa, J.C., Freiberg, B.A., Crawford, F., Kappler, J., Kupfer, A., et al. TCR-induced transmembrane signaling by peptide/MHC class II via associated Ig-alpha/beta dimers. Science 291 (2001), 1537–1540.
48. [48] Kurtz, C.B., O'Toole, E., Christensen, S.M., Weis, J.H., The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J. Immunol. 144 (1990), 3581–3591.
49. [49] Matsumoto, A.K., Kopicky-Burd, J., Carter, R.H., Tuveson, D.A., Tedder, T.F., Fearon, D.T., Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J. Exp. Med. 173 (1991), 55–64.
50. [50] Tuveson, D.A., Ahearn, J.M., Matsumoto, A.K., Fearon, D.T., Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J. Exp. Med. 173 (1991), 1083–1089.
51. [51] Phan, T.G., Grigorova, I., Okada, T., Cyster, J.G., Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat. Immunol. 8 (2007), 992–1000.
52. [52] Hammerberg, C., Katiyar, S.K., Carroll, M.C., Cooper, K.D., Activated complement component 3 (C3) is required for ultraviolet induction of immunosuppression and antigenic tolerance. J. Exp. Med. 187 (1998), 1133–1138.
53. [53] Stapelberg, M.P., Williams, R.B., Byrne, S.N., Halliday, G.M., The alternative complement pathway seems to be a UVA sensor that leads to systemic immunosuppression. J. Investig. Dermatol. 129 (2009), 2694–2701.
54. [54] Byrne, S.N., Hammond, K.J., Chan, C.Y., Rogers, L.J., Beaugie, C., Rana, S., et al. The alternative complement component factor B regulates UV-induced oedema, systemic suppression of contact and delayed hypersensitivity, and mast cell infiltration into the skin. Photochem. Photobiol. Sci. 14 (2015), 801–806.
55. [55] Lindner, S., Dahlke, K., Sontheimer, K., Hagn, M., Kaltenmeier, C., Barth, T.F., et al. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 73 (2013), 2468–2479.
56. [56] Sattler, S., Ling, G.S., Xu, D., Hussaarts, L., Romaine, A., Zhao, H., et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J. Autoimmun. 50 (2014), 107–122.
57. [57] van de Veen, W., Stanic, B., Yaman, G., Wawrzyniak, M., Söllner, S., Akdis, D.G., et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J. Allergy Clin. Immunol. 131 (2013), 1204–1212.
58. [58] Kessel, A., Haj, T., Peri, R., Snir, A., Melamed, D., Sabo, E., et al. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun. Rev. 11 (2012), 670–677.
59. [59] Byrne, S.N., Beaugie, C., O'Sullivan, C., Leighton, S., Halliday, G.M., The immune-modulating cytokine and endogenous alarmin Interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am. J. Pathol. 179 (2011), 211–222.
60. [60] Jiang, H.R., Milovanović, M., Allan, D., Niedbala, W., Besnard, A.G., Fukada, S.Y., et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur. J. Immunol. 42 (2012), 1804–1814.
61. [61] Toichi, E., Lu, K.Q., Swick, A.R., McCormick, T.S., Cooper, K.D., Skin-infiltrating monocytes/macrophages migrate to draining lymph nodes and produce IL-10 after contact sensitizer exposure to UV-irradiated skin. J. Investig. Dermatol. 128 (2008), 2705–2715.
62. [62] Yoshiki, R., Kabashima, K., Sakabe, J., Sugita, K., Bito, T., Nakamura, M., et al. The mandatory role of IL-10-producing and OX40 ligand-expressing mature Langerhans cells in local UVB-induced immunosuppression. J. Immunol. 184 (2010), 5670–5677.
63. [63] Mann, M.K., Maresz, K., Shriver, L.P., Tan, Y., Dittel, B.N., B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J. Immunol. 178 (2007), 3447–3456.
64. [64] Bodhankar, S., Wang, C., Vandenbark, A.A., Offner, H., Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. Eur. J. Immunol. 41 (2011), 1165–1175.
65. [65] Mak, T.W., Shahinian, A., Yoshinaga, S.K., Wakeham, A., Boucher, L.M., Pintilie, M., et al. Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses. Nat. Immunol. 4 (2003), 765–772.
66. [66] Hutloff, A., Dittrich, A.M., Beier, K.C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397 (1999), 263–266.
67. [67] Gajewska, B.U., Tafuri, A., Swirski, F.K., Walker, T., Johnson, J.R., Shea, T., et al. B7RP-1 is not required for the generation of Th2 responses in a model of allergic airway inflammation but is essential for the induction of inhalation tolerance. J. Immunol. 174 (2005), 3000–3005.
68. [68] Miyamoto, K., Kingsley, C.I., Zhang, X., Jabs, C., Izikson, L., Sobel, R.A., et al. The ICOS molecule plays a crucial role in the development of mucosal tolerance. J. Immunol. 175 (2005), 7341–7347.
69. [69] Dong, C., Juedes, A.E., Temann, U.A., Shresta, S., Allison, J.P., Ruddle, N.H., et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409 (2001), 97–101.
70. [70] Rottman, J.B., Smith, T., Tonra, J.R., Ganley, K., Bloom, T., Silva, R., et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat. Immunol. 2 (2001), 605–611.
71. [71] Rana, S., Byrne, S.N., Macdonald, L.J., Chan, C.Y., Halliday, G.M., Ultraviolet B suppresses immunity by inhibiting effector and memory T cells. Am. J. Pathol. 172 (2008), 993–1004.
72. [72] Nouël, A., Pochard, P., Simon, Q., Ségalen, I., Le Meur, Y., Pers, J.O., et al. B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner. J. Autoimmun. 59 (2015), 53–60.
73. [73] Kim, S.S., Richman, D.P., Zamvil, S.S., Agius, M.A., Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice. J. Neurol. Sci. 306 (2011), 9–15.
74. [74] Khan, A.R., Hams, E., Floudas, A., Sparwasser, T., Weaver, C.T., Fallon, P.G., PD-L1hi B cells are critical regulators of humoral immunity. Nat. Commun., 6, 2015, 5997.
75. [75] Krumbholz, M., Theil, D., Derfuss, T., Rosenwald, A., Schrader, F., Monoranu, C.M., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201 (2005), 195–200.
76. [76] Begum-Haque, S., Sharma, A., Christy, M., Lentini, T., Ochoa-Reparaz, J., Fayed, I.F., et al. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 219 (2010), 47–53.
77. [77] Zhou, X., Xia, Z., Lan, Q., Wang, J., Su, W., Han, Y.P., et al. BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One, 6, 2011 e23629.
78. [78] Hauser, S.L., Waubant, E., Arnold, D.L., Vollmer, T., Antel, J., Fox, R.J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358 (2008), 676–688.
79. [79] Sastre-Garriga, J., Wiendl, H., Highlights from the 31st ECTRIMS congress – Barcelona 2015. Multiple Scler. J. 22 (2016), 7–10.
80. [80] Kappos, L., Hartung, H.-P., Freedman, M.S., Boyko, A., Radü, E.W., Mikol, D.D., et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 13 (2014), 353–363.
81. [81] Naradikian, M.S., Perate, A.R., Cancro, M.P., BAFF receptors and ligands create independent homeostatic niches for B cell subsets. Curr. Opin. Immunol. 34 (2015), 126–129.
82. [82] Miyagaki, T., Fujimoto, M., Shinichi, S., Regulatory B cells in human inflammatory and autoimmune diseases: from mouse models to clinical research. Int. Immunol. 27 (2015), 495–504.